Polineuropatía desmielinizante inflamatoria crónica como forma de presentación de lupus eritematoso sistémico
Resumen
Se describe el caso de una mujer de 35 años que presenta polineuropatía desmielinizante inflamatoria crónica como compromiso neurológico en su diagnóstico inicial de lupus eritematoso sistémico (LES). Si bien el compromiso neurológico es de una prevalencia variable en lupus, la asociación que se describe no es frecuente y tiene importantes connotaciones en el tratamiento.Citas
I. Bortoluzzi, Alessandra; Sciré, Carlo Alberto; Govoni, Marcello. Attribution of neuropsychiatric manifestations to systemic lupus erythematosus. Frontiers in medicine, 2018, vol. 5, p. 68.
II. Liang, M et al The American College of Rheumatology nomenclature and case definition for neuropsychiatric lupus syndromes. Arthritis Rheum, 1999. 42:599–608.
III. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum, 1997. 40:1725. doi: 10.1002/ art.1780400928
IV. Vivaldo, Jessica Fernandes, et al. Definition of NPSLE: Does the ACR nomenclature still hold? Frontiers in medicine, 2018, vol. 5.
V. Oomatia, A., et al. Peripheral Neuropathies in Systemic Lupus Erythematosus: Clinical Features, Disease Associations, and Immunologic Characteristics Evaluated Over a Twenty‐Five–Year Study Period. Arthritis & Rheumatology, 2014, vol. 66, no 4, p. 1000-1009.
VI. Peltier, Amanda C.; Donofrio, Peter D. Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside. Seminars in neurology. Thieme Medical Publishers, 2012. p. 187-195.
VII. Abraham, Hrudya; Kuzhively, Jose; Rizvi, Syed W. Chronic inflammatory demyelinating polyneuropathy (CIDP): an uncommon manifestation of systemic lupus erythematosus (SLE). The American journal of case reports, 2017, vol. 18, p. 980.
VIII. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41:617-18
IX. Haq, Rizwan U., et al. Chronic inflammatory demyelinating polyradiculoneuropathy: a study of proposed electrodiagnostic and histologic criteria. Archives of neurology, 2000, vol. 57, no 12, p. 1745-1750.
X. Chiò, Adriano, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. Journal of Neurology, Neurosurgery & Psychiatry, 2007, vol. 78, no 12, p. 1349-1353.
XI. Köller, H; Kieseier, B; Jander, S; Hartung, S Chronic Inflammatory Demyelinating Polyneuropathy N Engl J Med 2005;352:1343-56
XII. Oaklander, Anne Louise, et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database of Systematic Reviews, 2017, no 1.
XIII. Adrichem, Max E., et al. Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC‐protocol); a prospective pilot study. European Journal of Neurology, 2019.
XIV. Cirillo, Giovanni, et al. Clinical‐neurophysiological correlations in chronic inflammatory demyelinating polyradiculoneuropathy patients treated with subcutaneous immunoglobulin. Muscle & nerve, 2019.
XV. Jasmin, R., et al. Successful treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in systemic lupus erythematosus (SLE) with oral cyclophosphamide. Lupus, 2012, vol. 21, no 10, p. 1119-1123.
